Approaches to Treatment2020 Spring
I
I I I
Test Week I6 IMidterm IExam
Status Completed
Attempt 72 I out I of I 75 I points
IScore
Time 1 Ihour, I36 Iminutes Iout Iof I2 Ihours
IElapsed
Results I Submitted IAnswers
IDisplaye
d
• Question 1 I
1 Iout Iof I1 Ipoints
Mr. McCullin is 64 years old with Parkinson’s disease. The
I I I I I I I I I
PMHNP caring for Mr. McCullin wants to start him on a
I I I I I I I I I I I
dopamine agonist to help manage and treat his condition. The
I I I I I I I I I I
PHMNP selects this agent because of which action it has on
I I I I I I I I I I I
patients like Mr. McCullin?
I I I I
Selected D.
IAnswer:
D2 receptors are the primary binding site for dopamine
I I I I I I I I
agonists.
I
• Question 2 I
1 Iout Iof I1 Ipoints
Ms. IHill Iis Icurrently I being Itreated Ifor I schizophrenia Ibut Ihas Istopped Itaking
Iher I medications I due I to I some I side I effects I she I claims I she I was
Iexperiencing. I She I presents I to I the I clinic I today I with I worsening I symptoms.
IShe Iis I experiencing Ianhedonia, I agitation, Iattentional Iimpairment, Iand
Iaffective I blunting. I Which I one I of I the I symptoms I mentioned I is I considered I a
Iprogressive Isymptom Iof Ischizophrenia?
Selected B.
IAnswer:
Agitation
• Question 3 I
1 Iout Iof I1 Ipoints
, The PMHNP evaluates the patient for “fear conditioning” when
I I I I I I I I
he asks:
I I
Selected A.
IAnswer:
Have you ever experienced any
I I I I
variety of trauma?
I I I
• Question 4 I
1 Iout Iof I1 Ipoints
While genes have potential to modify behavior, behavior can
I I I I I I I I
also modify genes. How do genes impact this process?
I I I I I I I I I
Selected B.
IAnswer:
Changes made to proteins lead to changes I I I I I I
in behavior.
I I
• Question 5 I
1 Iout Iof I1 Ipoints
The PMHNP is caring for a patient with schizophrenia and is
I I I I I I I I I I
considering a variety of treatment approaches. The PHMNP
I I I I I I I I
selects a viable treatment that is consistent with the
I I I I I I I I I
“dopamine hypothesis of schizophrenia.” What action does
I I I I I I I
the PMHNP anticipate this treatment having on the patient?
I I I I I I I I I
Selected B.
IAnswer:
Hyperactivity in the mesolimbic dopamine pathway I I I I I
mediates the positive symptoms of schizophrenia.
I I I I I I
• Question 6 I
1 Iout Iof I1 Ipoints
A patient is diagnosed with schizophrenia. What rises the patient’s
I I I I I I I I I
potential to mediate the cognitive symptoms of the disease?
I I I I I I I I I
Selected A.
IAnswer:
Achieving underactivity of the mesocorticol I I I I
projections to the prefrontal cortex
I I I I I
• Question 7 I
1 Iout Iof I1 Ipoints
, The PMHNP is assessing a patient in the psychiatric
I I I I I I I I
emergency room. The patient tells the PMHNP that he does
I I I I I I I I I I
not understand why his depression has not lifted after being
I I I I I I I I I I
on four different antidepressants over the course of a year.
I I I I I I I I I I
Which of the following symptoms can be residual symptoms
I I I I I I I I I
for patients who do not achieve remission with major
I I I I I I I I I
depressive disorder?
I I
Selected D.
IAnswer:
A and I
C
I
• Question 8 I
1 Iout Iof I1 Ipoints
Though medications have the ability to target neurotransmitter release into
I I I I I I I I I
the synapse by the presynaptic neuron it is not always necessary. The PMHNP
I I I I I I I I I I I I I
understands that this is because:
I I I I I
Selected
C.
IAnswer:
Neurotransmitters can spread by I I I
diffusion.
I
• Question 9 I
1 Iout Iof I1 Ipoints
A patient diagnosed with PTSD is prescribed propranolol (Inderal)
I I I I I I I I
and the PMHNP understands that he was prescribed this
I I I I I I I I I
medication for what purpose:
I I I I
Selected B.
IAnswer:
Beta blockers are linked to I I I I
reconsolidation.
I
• Question 10 I
1 Iout Iof I1 Ipoints
A patient presents with frequent episodes of mania. Which
I I I I I I I I
statement describes an appropriate treatment approach for
I I I I I I I
this patient?
I I
Selected B.
IAnswer:
“The patient could benefit from an I I I I I
anticonvulsant.”
I